New hope for safer cure of devastating immune disorder

This study is testing if a new drug called Briquilimab can make stem cell transplants safer for people with GATA2 deficiency, a genetic disorder that weakens the immune system and can lead to blood cancers. Participants receive Briquilimab as part of their preparation for a transplant of donor stem cells, aiming to reduce the severe side effects common with standard transplant procedures. The main goal is to see if the new approach successfully allows the donor cells to take hold and restore healthy blood cell production.